Navidea Biopharmaceuticals Nachrichten und Aktivitäten

Navidea Biopharmaceuticals ist ein Unternehmen, das unter dem Börsenticker NAVB (US) gelistet ist.

Siehe das Organigramm mit seine 3 wichtigsten Führungskräfte

Die meist gesuchten Biographien bei Navidea Biopharmaceuticals

• John Scott, Vice Chairman of the Board
• Craig Dais, Chief Financial Officer
• Michael Sherman, Chief Medical Officer

Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Navidea Biopharmaceuticals nachzuverfolgen.

Navidea Biopharmaceuticals hat 1.837 Konkurrenten , einschließlich Pfizer (USA), Johnson & Johnson (USA) und Sanofi (Frankreich).

Popular M&A news in Pharmazie

• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (veröffentlicht am 16, Juni 2025).
• Juvenescence hat gerade eine Spendenaktion von 76 Millionen Dollar angekündigt. (veröffentlicht am 22, Mai 2025).
• Kincell Bio hat gerade eine Spendenaktion von 22 Millionen Dollar angekündigt. (veröffentlicht am 22, Mai 2025).

Andere vorgeschlagene Kontakte der Pharmazie branche

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets bei Bristol-Myers Squibb
• Amanda Moore - Vice President, Program Leadership and Clinical Operations bei Abeona Therapeutics
• Jean-Michel Demeure - Vice President, Finance Global Operations bei Sanofi

Mehr über die Pharmazie branche erfahren

Neueste Pressemitteilungen nach Navidea Biopharmaceuticals

• Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024 :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer :: Navidea Biopharmaceuticals, Inc. (NAVB)
• Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination :: Navidea Biopharmaceuticals, Inc. (NAVB)
• View more press releases Close

Social media about Navidea Biopharmaceuticals

• Navidea Biopharmaceuticals auf Wikipedia, Google News & Yahoo Finance
• Navidea Biopharmaceuticals auf LinkedIn, Twitter & YouTube